Skip to main content

Foley & Lardner LLP represented TCGX as a lead investor in the oversubscribed $200 million Series C financing for ADARx, a leader in next generation RNA Therapeutics. TCGX led the round jointly with Bain Capital Life Sciences.

ADARx is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA delivery platforms and technology for silencing or editing target mRNA and has a growing pipeline of RNA therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiovascular, complement-mediated, and central nervous system.

Funding will be used to further advance ADARx clinical programs including ADX-324 and ADX-038. ADX-324 represents an innovative approach for the treatment of hereditary angioedema, a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks, while ADX-038 is being developed for the treatment of multiple complement mediated diseases. The funding will also support advancement of a pipeline of innovative mRNA silencing or editing candidates for the treatment of a broad range of diseases.

The Foley team was led by partner Louis Lehot and included partners Rishi Sodhi and Lyman Thai and associate Ethan Floyd.

Foley’s Venture & Growth Capital attorneys understand the complex and diverse needs of both venture funds and their portfolio companies and offer a broad range of services at each stage of development. The attorneys have insight into the unique needs of high-growth companies operating in the technology, life science, smart manufacturing, and clean energy sectors.

Foley’s Life Sciences Team is composed of corporate, health care, regulatory, and IP attorneys whose comprehensive approach guides start-ups and established enterprises in the life sciences industry through fluctuating global financial markets, a rapidly changing IP environment, and regulatory hurdles that can impact the products they bring to market. For decades, our attorneys have partnered with life sciences companies at all stages of development to help them make their mark on the industry.

Author Louis Lehot

More Insights by Louis Lehot